Belatacept BMS 224818; LEA 29Y|cas:706808-37-9|西域试剂

Belatacept BMS 224818; LEA 29Y,98.00%

产品编号：Bellancom-108813| CAS NO：706808-37-9

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-108813	￥2000.00	杭州北京（现货）
Bellancom-108813	￥5600.00	杭州北京（现货）
Bellancom-108813	￥9000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Belatacept BMS 224818; LEA 29Y

产品介绍

Belatacept (BMS 224818) 是一种选择性 T 细胞共刺激 (T-cell costimulation) 阻滞剂。Belatacept 与 CD 80/86 配体结合而抑制 CD-28 介导的 T 细胞共刺激。Belatacept 可用于器官移植免疫抑制的研究。

生物活性

Belatacept (BMS 224818) is a selective T-cell costimulation blocker. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants.

体外研究

Belatacept (0-5 mg/mL, 1 h) inhibits T-cell proliferation in a dose-dependent manner.
Belatacept (500 ng/mL, 7 days) enhances predominance of effector-memory T-cells after allogeneic stimulation.
Belatacept (100, 500 ng/mL, 7 days) has no effect on differentiation and allogeneic IFNγ production of isolated effector-memory T cells.
Belatacept (10 μg/mL, 1 h) does not inhibit follicular T Cell-dependent B-Cell differentiation^[4].
Belatacept (40 μg/mL, 10 days) reduces plasmablast differentiation, Ig production, and the major transcription factor Blimp-1 in a T cell-independent manner^[5].
Belatacept (40 μg/mL, 30 min) induces activation of the STAT3 transcription factor in stimulated B cells and reduced the expression of CD86^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	PBMCs from healthy volunteers
Concentration:	0-5 mg/mL
Incubation Time:	1 h
Result:	Inhibited T-cell proliferation l with IC₅₀ values of 215 ng/mL, and residual T-cell proliferation (±30%) was still present at high doses.

Western Blot Analysis^[5]

Cell Line:	CD40L and IL-21 stimulated B cells
Concentration:	40 μg/mL
Incubation Time:	15, 30 min
Result:	Increased in STAT signaling determined by increased STAT3 phosphorylation.

体内研究
(In Vivo)

Belatacept (intraperitoneal injection, 60 mg/kg) inhibits ABMR (Antibody-Mediated Rejection), and inhibits acute rejection when combined with BTLA (B and T lymphocyte attenuator) overexpression therapy.
Belatacept (intravenous injection, 20 mg/kg) displays immunosuppressive activities in monkeys immunized with sheep red blood cell^[6].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Acute rejection model of orthotopic kidney transplantation in rats
Dosage:	60 mg/kg
Administration:	Intraperitoneal injection, at postoperative and 4 days after transplantation.
Result:	Inhibited creatinine increase after kidney transplantation (combined with BTLA overexpression therapy). Reduced C4d in graft IF staining, and reduced CD138 infiltration and DSA production.

Animal Model:	Rhesus monkeys immunized with sheep red blood cell^[6]
Dosage:	Intra-operatively 10 mg/kg, on day 4 (15 mg/kg) and on post-operative days 14, 28, 42, 56, 70 (20 mg/kg).
Administration:	intravenous injection
Result:	Caused a 50% reduction in the peak anti-SRBC response. Prolonged renal allograft survival and synergies with conventional immunosuppression.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Acute rejection model of orthotopic kidney transplantation in rats
Dosage:	60 mg/kg
Administration:	Intraperitoneal injection, at postoperative and 4 days after transplantation.
Result:	Inhibited creatinine increase after kidney transplantation (combined with BTLA overexpression therapy). Reduced C4d in graft IF staining, and reduced CD138 infiltration and DSA production.

Animal Model:	Rhesus monkeys immunized with sheep red blood cell^[6]
Dosage:	Intra-operatively 10 mg/kg, on day 4 (15 mg/kg) and on post-operative days 14, 28, 42, 56, 70 (20 mg/kg).
Administration:	intravenous injection
Result:	Caused a 50% reduction in the peak anti-SRBC response. Prolonged renal allograft survival and synergies with conventional immunosuppression.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Acute rejection model of orthotopic kidney transplantation in rats
Dosage:	60 mg/kg
Administration:	Intraperitoneal injection, at postoperative and 4 days after transplantation.
Result:	Inhibited creatinine increase after kidney transplantation (combined with BTLA overexpression therapy). Reduced C4d in graft IF staining, and reduced CD138 infiltration and DSA production.

Animal Model:	Rhesus monkeys immunized with sheep red blood cell^[6]
Dosage:	Intra-operatively 10 mg/kg, on day 4 (15 mg/kg) and on post-operative days 14, 28, 42, 56, 70 (20 mg/kg).
Administration:	intravenous injection
Result:	Caused a 50% reduction in the peak anti-SRBC response. Prolonged renal allograft survival and synergies with conventional immunosuppression.